Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -8.22%-590.9M | ---- | -13.45%-546.02M | ---- | -28.26%-481.27M | ---- | 27.13%-375.24M | ---- | -189.24%-514.97M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | 66.67%-10K | ---- | 36.17%-30K | ---- | 25.40%-47K | ---- | 72.61%-63K | ---- | -475.00%-230K |
| Impairment and provisions: | ---- | -25.96%80.78M | ---- | 124.82%109.1M | ---- | 749.89%48.53M | ---- | -97.23%5.71M | ---- | 1,195.59%206.3M |
| -Impairment of property, plant and equipment (reversal) | ---- | -23.03%71.36M | ---- | 97.28%92.71M | ---- | 723.01%46.99M | ---- | -96.19%5.71M | ---- | 1,221.23%149.92M |
| -Impairment of trade receivables (reversal) | ---- | -240.16%-862K | ---- | -59.93%615K | ---- | --1.54M | ---- | ---- | ---- | --4.25M |
| -Other impairments and provisions | ---- | -34.83%10.28M | ---- | --15.78M | ---- | ---- | ---- | ---- | ---- | 1,039.07%52.12M |
| Revaluation surplus: | ---- | 8.76%266.11M | ---- | 24.56%244.68M | ---- | 151.30%196.43M | ---- | 4,301.18%78.17M | ---- | -93.98%1.78M |
| -Fair value of investment properties (increase) | ---- | 8.76%266.11M | ---- | 26.20%244.68M | ---- | 179.52%193.89M | ---- | 1,596.82%69.37M | ---- | -85.56%4.09M |
| -Other fair value changes | ---- | ---- | ---- | ---- | ---- | -71.12%2.54M | ---- | 480.58%8.8M | ---- | -296.26%-2.31M |
| Asset sale loss (gain): | ---- | ---- | ---- | ---- | ---- | --19K | ---- | ---- | ---- | ---- |
| -Loss (gain) on sale of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | --19K | ---- | ---- | ---- | ---- |
| Depreciation and amortization: | ---- | -15.01%23.03M | ---- | -31.59%27.09M | ---- | -9.98%39.6M | ---- | -11.20%43.99M | ---- | 129.64%49.54M |
| Financial expense | ---- | 51.97%208.54M | ---- | -18.28%137.22M | ---- | -9.53%167.92M | ---- | 20.21%185.6M | ---- | 57.06%154.4M |
| Special items | ---- | -117.40%-728K | ---- | 1,552.78%4.18M | ---- | 45.76%-288K | ---- | -102.90%-531K | ---- | --18.32M |
| Operating profit before the change of operating capital | ---- | 44.46%-13.2M | ---- | 18.36%-23.76M | ---- | 53.34%-29.1M | ---- | 26.51%-62.37M | ---- | -432.73%-84.86M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -79.66%12K | ---- | -98.56%59K | ---- | 435.64%4.1M | ---- | 249.90%766K | ---- | -259.86%-511K |
| Developing property (increase)decrease | ---- | ---- | ---- | -14.09%7.7M | ---- | --8.96M | ---- | ---- | ---- | 206.58%51.17M |
| Accounts receivable (increase)decrease | ---- | 155.63%5.42M | ---- | -95.82%-9.74M | ---- | -124.43%-4.98M | ---- | 191.50%20.37M | ---- | -1,148.68%-22.26M |
| Accounts payable increase (decrease) | ---- | 146.67%12.41M | ---- | -183.25%-26.6M | ---- | 176.42%31.95M | ---- | -17.45%-41.81M | ---- | -163.60%-35.59M |
| Special items for working capital changes | ---- | -187.63%-8.98M | ---- | 203.14%10.24M | ---- | -142.93%-9.93M | ---- | 77.54%-4.09M | ---- | ---18.2M |
| Cash from business operations | ---- | 89.73%-4.33M | ---- | -4,305.89%-42.1M | ---- | 101.15%1M | ---- | 20.98%-87.12M | ---- | -301.21%-110.26M |
| Other taxs | ---- | 59.73%-1.53M | ---- | -4.12%-3.79M | ---- | 46.40%-3.64M | ---- | -289.33%-6.79M | ---- | ---1.74M |
| Special items of business | 91.34%-1.31M | ---- | -40.87%-15.1M | ---- | 25.84%-10.72M | ---- | 72.46%-14.45M | ---- | -167.69%-52.48M | ---- |
| Net cash from operations | 91.34%-1.31M | 87.25%-5.85M | -40.87%-15.1M | -1,640.82%-45.89M | 25.84%-10.72M | 97.19%-2.64M | 72.46%-14.45M | 16.16%-93.91M | -167.69%-52.48M | -304.39%-112M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | -60.00%2K | -66.67%10K | -73.68%5K | -36.17%30K | -40.63%19K | -25.40%47K | 39.13%32K | -72.61%63K | -84.67%23K | 475.00%230K |
| Loan receivable (increase) decrease | -328.57%-6.21M | 70.81%-949K | 74.71%-1.45M | -591.09%-3.25M | -364.64%-5.73M | 1,282.14%662K | -126.53%-1.23M | -113.83%-56K | 1,095.07%4.65M | 119.03%405K |
| Sale of fixed assets | ---- | ---- | ---- | --25K | --13K | ---- | ---- | ---- | ---- | ---- |
| Purchase of fixed assets | -1,716.67%-109K | 0.60%-167K | 91.30%-6K | 95.38%-168K | 97.45%-69K | -4.10%-3.63M | -90.58%-2.71M | -2.89%-3.49M | 89.87%-1.42M | 96.73%-3.39M |
| Sale of subsidiaries | ---10.02M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Acquisition of subsidiaries | ---- | ---2.96M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.88M |
| Cash on investment | ---- | ---- | ---- | ---- | ---27K | 3.58%-6.47M | ---- | 83.57%-6.71M | ---- | 9.98%-40.84M |
| Net cash from investment operations | -1,026.76%-16.34M | -20.90%-4.07M | 74.97%-1.45M | 64.19%-3.36M | -48.12%-5.79M | 7.84%-9.39M | -220.41%-3.91M | 75.57%-10.19M | 108.63%3.25M | 73.48%-41.72M |
| Net cash before financing | -6.64%-17.65M | 79.86%-9.92M | -0.22%-16.55M | -309.41%-49.25M | 10.09%-16.51M | 88.44%-12.03M | 62.70%-18.36M | 32.28%-104.1M | 13.97%-49.23M | -49.95%-153.72M |
| Cash flow from financing activities | ||||||||||
| New borrowing | -59.98%7.75M | -45.55%33.25M | -34.97%19.37M | -79.12%61.07M | -61.43%29.78M | -51.46%292.47M | -84.41%77.21M | 104.85%602.59M | 34,502.66%495.16M | -81.32%294.16M |
| Refund | ---- | 64.94%-3.38M | 52.75%-1.44M | 94.74%-9.64M | 15.34%-3.05M | 64.96%-183.19M | 99.29%-3.61M | 60.30%-522.86M | 53.88%-509.82M | -986.43%-1.32B |
| Issuing shares | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --50.43M |
| Interest paid - financing | ---- | -55.83%-9.09M | 99.91%-6K | 93.51%-5.83M | 87.09%-6.58M | 14.50%-89.77M | 3.78%-50.98M | 3.38%-105M | -7.80%-52.99M | 8.49%-108.67M |
| Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---1.04M |
| Other items of the financing business | 2,000.00%105K | 561.43%463K | -83.33%5K | -75.69%70K | --30K | -45.76%288K | ---- | -36.18%531K | ---- | --832K |
| Net cash from financing operations | -55.44%7.86M | -66.78%14.72M | -7.80%17.63M | 151.47%44.32M | -9.14%19.12M | 159.52%17.63M | 129.93%21.04M | 97.28%-29.61M | 93.64%-70.3M | -181.80%-1.09B |
| Effect of rate | 209.21%676K | 95.19%-428K | 64.24%-619K | -97.84%-8.9M | 69.92%-1.73M | -138.45%-4.5M | -260.55%-5.75M | -11.67%11.7M | -53.54%3.58M | 222.80%13.24M |
| Net Cash | -1,005.74%-9.79M | 197.52%4.81M | -58.58%1.08M | -188.06%-4.93M | -2.65%2.61M | 104.19%5.6M | 102.24%2.68M | 89.23%-133.71M | 89.73%-119.53M | -201.17%-1.24B |
| Begining period cash | 22.99%23.42M | -42.06%19.04M | -42.06%19.04M | 3.46%32.87M | 3.46%32.87M | -79.34%31.77M | -79.34%31.77M | -88.87%153.79M | -88.87%153.79M | 733.91%1.38B |
| Cash at the end | -26.65%14.31M | 22.99%23.42M | -42.20%19.51M | -42.06%19.04M | 17.60%33.75M | 3.46%32.87M | -24.16%28.7M | -79.34%31.77M | -83.24%37.84M | -88.87%153.79M |
| Cash balance analysis | ||||||||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Zhongzheng Tianheng Certified Public Accountants Co., Ltd. | -- | Zhongzheng Tianheng Certified Public Accountants Co., Ltd. | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.